<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383288</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS-33</org_study_id>
    <nct_id>NCT04383288</nct_id>
  </id_info>
  <brief_title>ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities</brief_title>
  <official_title>Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-authorization, observational, multicenter and prospective study in patients between 2&#xD;
      and 30 years old diagnosed with non-metastatic high-grade osteosarcoma of the extremities.&#xD;
&#xD;
      All patients included in the study will receive the initial neoadjuvant treatment prescribed&#xD;
      by the doctor of each center, according to standard practice (involving methotrexate,&#xD;
      cisplatin, and adriamycin). This initial treatment precedes surgical treatment.&#xD;
&#xD;
      After surgical treatment, the histological response to neoadjuvant chemotherapy will be&#xD;
      evaluated. The histological response to primary chemotherapy will be expressed as a&#xD;
      percentage of tumor necrosis. In the case of tumor necrosis above 90% the patient is defined&#xD;
      as a &quot;good responder&quot; in case of a lower percentage as a &quot;poor responder&quot;.&#xD;
&#xD;
      As an adjuvant treatment, the following options may be given according to standard practice&#xD;
      in each center:&#xD;
&#xD;
        1. - If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction&#xD;
           treatment, in many sites ifosfamide at high doses and MTP-PE, is incorporated in&#xD;
           addition to adriamycin.&#xD;
&#xD;
        2. - If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction&#xD;
           treatment, in many centers the option of additional administration of methotrexate, CDDP&#xD;
           and adriamycin will be chosen.&#xD;
&#xD;
        3. - If there is no overexpression of ABCB1 / P-glycoprotein, the administration of&#xD;
           methotrexate, adriamycin and cisplatin will be chosen in many sites.&#xD;
&#xD;
      In some sites they will consider the non-administration of MTP-PE or the non-administration&#xD;
      of high doses of ifosfamide. And, in some hospitals, they will consider administering MTP-PE&#xD;
      to all patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary objective is:&#xD;
&#xD;
      - Disease-free survival measured as a 5-year rate in patients with localized osteosarcoma&#xD;
      treated, according to standard practice, with all the drugs currently registered for the&#xD;
      treatment of non-metastatic osteosarcoma (methotrexate, cisplatin, adriamycin, ifosfamide,&#xD;
      MTP-PE), according to ABCB1 / P-glycoprotein expression.&#xD;
&#xD;
      The Secondary objectives are:&#xD;
&#xD;
        -  Evaluate overall survival in a homogeneous population of patients with non-metastatic&#xD;
           osteosarcoma.&#xD;
&#xD;
        -  Disease-free survival at 2 and 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2014</start_date>
  <completion_date type="Actual">October 17, 2020</completion_date>
  <primary_completion_date type="Actual">October 17, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The patients will be followed in term of Overall Survival, for all the study period (expected average: 7 years)</time_frame>
    <description>The Overall Survival will be evaluated at the end of the study period (5 enrollment years and 2 years - minimum- follow-up from the last enrolled patient)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Events free survival</measure>
    <time_frame>After 2 and 3 years from the start of study</time_frame>
    <description>The events free survival will be evaluated by means of interim analysis after 2 and 3 years from the start of study. A further evaluation will be performed at the end of enrollment and after 2 years form the last enrolled patient.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">115</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Overexpression of ABCB1 / P-glycoprotein. Poor response</arm_group_label>
    <description>If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.&#xD;
BEFORE SURGERY TREATMENT:&#xD;
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)&#xD;
AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)&#xD;
All the product are used as commercial formulation&#xD;
Other Names:&#xD;
Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overexpression of ABCB1 / P-glycoprotein. Good response</arm_group_label>
    <description>If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.&#xD;
BEFORE SURGERY TREATMENT:&#xD;
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)&#xD;
AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)&#xD;
All the product are used as commercial formulation&#xD;
Other Names:&#xD;
Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No overexpression of ABCB1 / P-glycoprotein</arm_group_label>
    <description>If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.&#xD;
BEFORE SURGERY TREATMENT:&#xD;
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)&#xD;
AFTER SURGERY TREATMENT:&#xD;
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2&#xD;
Total length 34 weeks&#xD;
All the product are used as commercial formulation&#xD;
Other Names:&#xD;
methotrexate cisplatin doxorubicine</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from peripheral blood samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 2 to 30 years old diagnosed with non-metastatic high-grade osteosarcoma of&#xD;
        the extremities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed histological diagnosis of high-grade osteosarcoma of the extremities.&#xD;
&#xD;
          2. Age: from 2 to 30 years old.&#xD;
&#xD;
          3. Localized disease (metastasis skip accepted).&#xD;
&#xD;
          4. Normal liver, kidney and spinal function.&#xD;
&#xD;
          5. Ventricular ejection fraction of 50%.&#xD;
&#xD;
          6. Absence of previous surgical treatments or chemotherapy for osteosarcoma.&#xD;
&#xD;
          7. Interval between histological diagnosis and initiation of chemotherapy not exceeding 4&#xD;
             weeks.&#xD;
&#xD;
          8. Signing of the consent form to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of lung metastases on chest CT or in other locations.&#xD;
&#xD;
          2. Parosteal, periosteal, or secondary osteosarcoma.&#xD;
&#xD;
          3. Contraindications of the medications prescribed in the protocol.&#xD;
&#xD;
          4. Pregnant or lactating.&#xD;
&#xD;
          5. Mental or social conditions that do not guarantee adequate adherence to the protocol.&#xD;
&#xD;
          6. Not having an adequate understanding of study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Óscar Gallego, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Gros, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infantil Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

